LIPOSARCOMA

This study tests whether a higher dose of proton radiation can better control soft tissue sarcomas that cannot be surgically removed. About 40 adults in Norway will receive radiation over 4 weeks, with the highest dose focused on the tumor center. The main goal is to see if the t…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. The goal is to see if adding the targeted drug pazopanib (and another drug, selinexor, for high-risk patients) to standard chemotherapy and radiation can…

This early-stage trial tests a new treatment for children and young adults with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The m…

This early-phase trial tests a new treatment called CARE T cells for children whose solid tumors (like liver cancer or Wilms tumor) have returned or not responded to standard care. The treatment involves taking a patient's own immune cells, adding special genes to help them recog…

This study tests whether giving a shorter course of radiation (3 weeks instead of longer) before surgery for soft tissue sarcoma can reduce long-term side effects. Each patient's treatment is personalized by choosing between proton or standard X-ray radiation. The study will enro…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma or sarcoma) have come back or not responded to treatment. The goal is to find a safe dose and see if the c…

This study tests whether giving chemotherapy before surgery helps people with high-risk retroperitoneal sarcoma (a rare cancer in the abdomen) live longer without the cancer coming back. About 250 adults with specific sarcoma types will be randomly assigned to receive chemo then …

This study tests whether two drugs, mirdametinib and palbociclib, can safely control advanced liposarcoma that has spread or cannot be removed by surgery. About 54 adults with this rare cancer will receive different doses to find the best balance of safety and effectiveness. The …

This study is gathering tissue samples and medical information from 800 people with high-risk soft tissue sarcomas. The goal is to learn how to personalize chemotherapy before surgery, using genetic and protein profiles. Participants either receive standard chemo plus surgery or …